학술논문

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Document Type
journal article
Source
Journal of Clinical Oncology; 8/202021, Vol. 39 Issue 24, p2647-2655, 9p
Subject
Language
ISSN
0732183X